Enanta Pharmaceuticals, Inc. (ENTA) - NASDAQ
  • Tue, Feb. 9, 12:48 PM
    | Tue, Feb. 9, 12:48 PM
  • Aug. 7, 2015, 5:40 PM
    | Aug. 7, 2015, 5:40 PM | 7 Comments
  • Jul. 24, 2015, 5:31 PM
    • Signet Jewlers (NYSE:SIG) is replacing DirecTV (just acquired by AT&T) in the S&P 500 after Tuesday's close. Parexel (NASDAQ:PRXL) is taking Signet's spot in the S&P MidCap 400, and Enanta Pharma (NASDAQ:ENTA) is taking Parexel's spot in the S&P SmallCap 600.
    • Also: Catalent (NYSE:CTLT) is replacing JDS Uniphase (JDSU - about to carry out a spinoff) in the S&P 400 after the July 31 close. What's left of JDSU (to be known as Viavi) will replace Susquehanna Bancshares (about to be acquired) in the S&P 600, while its Lumentum Holdings spinoff will replace Comstock Resources (NYSE:CRK) in the 600.
    • SIG +2.5% AH. PRXL +0.7%. ENTA +4%. CTLT +3%.
    | Jul. 24, 2015, 5:31 PM
  • Feb. 6, 2015, 5:37 PM
    | Feb. 6, 2015, 5:37 PM
  • Dec. 22, 2014, 9:17 AM
    | Dec. 22, 2014, 9:17 AM | 7 Comments
  • Dec. 22, 2014, 7:53 AM
    • AbbVie (NYSE:ABBV) is up 4% on moderately-higher volume and Enanta Pharmaceuticals (NASDAQ:ENTA) is up 11% on light volume in response to AbbVie's deal with Express Scripts (NASDAQ:ESRX).
    • Gilead Sciences (NASDAQ:GILD) is off 7% on high volume.
    • Previously: AbbVie's new hepatitis C drug gets boost (Dec. 22, 2014)
    | Dec. 22, 2014, 7:53 AM | 31 Comments
  • Jan. 31, 2014, 12:46 PM
    | Jan. 31, 2014, 12:46 PM
  • Jan. 31, 2014, 9:46 AM
    • AbbVie (ABBV) +3.5% in early trading despite reporting a 27% Y/Y drop in Q4 earnings, as the company releases positive results on its final-phase clinical trials for a promising new drug to treat certain patients with hepatitis C.
    • ABBV says it is on track to begin major regulatory submissions of the drug early in Q2.
    • ABBV’s blockbuster drug Humira eclipsed $10B in sales in 2013, making it the highest-grossing drug in the world; sales of the drug rose 13.4% during Q4 to $3.04B.
    • Overall net sales fell 1.8% to $5.11B, despite the Humira figures; sales of its Niaspan, TriCor and Trilipix cholesterol drugs fell by nearly 90% because of the introduction of generics..
    • Sees FY 2014 EPS of $3.00-$3.10 vs $3.16 analyst consensus estimate and revenue of $19B vs. $19.12B consensus; results exclude any potential revenue from the expected 2014 launch of the hepatitis C drug.
    • Shares of Enanta Pharmaceuticals (ENTA +14%), a close ABBV partner, are up sharply.
    | Jan. 31, 2014, 9:46 AM | 1 Comment
  • Jan. 31, 2014, 9:09 AM
    | Jan. 31, 2014, 9:09 AM | 4 Comments
  • Dec. 18, 2013, 12:45 PM
    | Dec. 18, 2013, 12:45 PM
  • Dec. 18, 2013, 10:56 AM
    • Shares of Enanta (ENTA -15.4%) are getting hit hard in morning trading.
    • Likely behind the move is upbeat data from GILD regarding impressive SVR12 rates from Phase 3 studies of a sofosbuvir/ledipasvir combo in GT1 HCV.
    • ENTA discovered ABT-450, one of the compounds in ABBV's 3D GT1 HCV regimen.
    • For more on ENTA/ABBV, see here and here.
    | Dec. 18, 2013, 10:56 AM
  • Dec. 10, 2013, 12:45 PM
    | Dec. 10, 2013, 12:45 PM
  • Nov. 27, 2013, 3:49 PM
    • Shares of Enanta (ENTA +6.7%) are hitting new highs today on above average volume.
    • Helping the cause is Leerink, where analysts have upgraded the shares to Outperform.
    • Price target is $29.
    • See also: AbbVie reports SAPPHIRE-1 HCV results.
    | Nov. 27, 2013, 3:49 PM
  • Aug. 12, 2013, 2:34 PM
    • Enanta Pharmaceuticals (ENTA +6%) moves up after beating FQ3 estimates earlier this morning.
    • EPS losses came in at $0.23 per share, on revenues of $1.6M.
    • Analysts expected loss per share of $0.31.
    • In the same period last year, net loss was $3.5M, or $4.31 per share, on revenues of $2.5M.
    • Cash and equivalents totaled $114.8M at the end of June, compared to $45.4M on September 30, 2012.
    • The company expects that its current cash, cash equivalents and marketable securities will be sufficient to meet anticipated requirements for at least the next 24 months.
    | Aug. 12, 2013, 2:34 PM
  • Apr. 15, 2013, 2:29 PM
    With the quiet period out of the way, a number of firms initiate coverage on recent IPO Enanta Pharmaceuticals (ENTA +2.6%) today; JPMorgan with an Overweight, and Lerrink Swann and Credit Suisse both with an Outperform (I, II). CSFB says that using conservative assumptions, the HCV market could reach $13B by 2020, which translates to a doubling of patients treated. Enanta develops drugs for the treatment of a number of various infectious diseases, with HCV being one of its key areas.
    | Apr. 15, 2013, 2:29 PM
  • Mar. 21, 2013, 5:55 PM

    Today's IPO of Enanta Pharmaceuticals (ENTA) closed +22.7% at $17.18 per share despite initially pricing 4M shares of its common stock at $14, the low-end of the expected $14-$16 range. JPMorgan and Credit Suisse acted as joint book-running managers for the IPO. Leerink Swann and JMP Securities were co-managers.

    | Mar. 21, 2013, 5:55 PM
Company Description
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company, which uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. It is discovering, and in some cases developing, novel... More
Sector: Healthcare
Industry: Biotechnology
Country: United States